We are live on ! Find out more
CKPT

Checkpoint Therapeutics

Delisted

CKPT was delisted on the 29th of May, 2025.

69 hedge funds and large institutions have $32.3M invested in Checkpoint Therapeutics in 2021 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 17 increasing their positions, 19 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

27% more call options, than puts

Call options by funds: $819K | Put options by funds: $647K

0.85% less ownership

Funds ownership: 2.38%1.52% (-0.85%)

5% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 20

1% less funds holding

Funds holding: 7069 (-1)

11% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 19

36% less capital invested

Capital invested by funds: $50.6M → $32.3M (-$18.3M)

Holders
69
Holders Change
-1
Holders Change %
-1.43%
% of All Funds
1.2%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
19
Increased
17
Reduced
19
Closed
20
Calls
$819K
Puts
$647K
Net Calls
+$172K
Net Calls Change
+$169K

CKPT Hedge Fund Activity: Q2 2021 in Review

69 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Checkpoint Therapeutics (CKPT) for Q2 2021, worth a combined $32.3M — down 36% from $50.6M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of CKPT and 19 opened new positions — a net loss of 1 holder — while 19 trimmed existing stakes and 17 added.

The largest buyer was Millennium Management, adding an estimated $2.49M. The largest seller was Opaleye Management, exiting entirely with an estimated $9.19M sold.

  • 69 institutional investors held Checkpoint Therapeutics (CKPT) as of Q2 2021, down from 70 in Q1 2021.
  • Funds reported $32.3M of Checkpoint Therapeutics stock for Q2 2021, down 36% quarter-over-quarter.
  • 19 funds opened new Checkpoint Therapeutics positions in Q2 2021 and 20 closed out, a net change of -1 holder.
  • The largest Checkpoint Therapeutics buyer in Q2 2021 was Millennium Management, an estimated $2.49M added.
  • The largest Checkpoint Therapeutics seller in Q2 2021 was Opaleye Management, an estimated $9.19M sold.

Based on aggregated 13F filings for Q2 2021.